• Login
• Register

HARDWARE AND SOFTWARE SPECIFICATIONS NEEDED TO VIEW SITE

This course requires Windows Operating Systems (95/98, NT, 2000, ME, XP), version 5.5 browsers or higher from Microsoft or Netscape.

Certain activities may require additional software to view multimedia, presentation, or printable versions of the content. These activities will be marked as such and will provide links to the required software. That software may be: Macromedia Flash, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, and Real Networks Real One Player.

ACCREDITATION STATEMENT

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the Elsevier Office of Continuing Medical Education (EOCME) and Excerpta Medica, Inc. The EOCME is accredited by the ACCME to provide continuing medical education (CME) for physicians.

CREDIT DESIGNATION STATEMENT

DISCLOSURES

As a sponsor accredited by the ACCME, it is the policy of the EOCME to require the disclosure of anyone who is in a position to control the content of an educational activity. All relevant financial relationships with any commercial interests and/or manufacturers must be disclosed to participants at the beginning of each activity. The faculties of this CME activity disclose the following:

RESOLUTION OF CONFLICT OF INTEREST

UNAPPROVED/OFF-LABEL USE DISCLOSURE

The EOCME requires CME faculty to disclose to the participants:

1. When products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not US Food and Drug Administration [FDA] approved); and
2. Any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion.

Faculty may discuss information about pharmaceutical agents that is outside of FDA-approved labeling. This information is intended solely for CME and is not intended to promote off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information.

INTENDED AUDIENCE

This activity has been developed for cardiologists, interventional cardiologists, emergency medicine physicians, hospitalists, and other health care providers who treat patients in a hospital setting.

PROGRAM GOALS

Participants should be able to understand updated guideline-based recommendations for the treatment of patients with non–ST-elevation myocardial infarction (NSTEMI) acute coronary syndromes (ACS) who may or may not undergo percutaneous coronary intervention (PCI). Participants should also be able to understand risk stratification and develop optimal therapeutic regimens when treating patients with NSTEMI. Completion of this activity should also be accompanied by an understanding of recent clinical trials and their impact in guideline generation.

EDUCATIONAL OBJECTIVES

• Stratify patients who present with ACS in terms of their risk for myocardial infarction (MI) or death
• Identify important new objectives and recommendations for the management of NSTEMI including patients who undergo PCI
• Use the results of recent clinical trials to guide the selection of antithrombin and antiplatelet agents in patients with NSTEMI
• Evaluate current practice standards to determine their accordance with current American College of Cardiology (ACC)/American Heart Association (AHA) guidelines
• Compare and contrast the updated 2007 NSTEMI Guidelines with the 2002 Guidelines

FINANCIAL SUPPORT

CME PLANNING COMMITTEE

CME INQUIRIES

SPECIAL NEEDS

We encourage participation by all individuals. If you have any special needs, please contact Wendy Barker at (908) 547-2183 or w.barker@elsevier.com for assistance.

Release date: February 2008